BioSpring GmbH
Anja Hofmann currently serves as QA-Manager and QA-Manager Stability at BioSpring GmbH since December 2020, bringing extensive experience in quality assurance and process management. Previously, Anja held the position of Prozessspezialist at GSK, where responsibilities included planning and coordinating change control procedures, conducting risk assessments, and preparing for regulatory inspections. Anja also contributed as a PhD researcher at TU Darmstadt in the field of chemistry, focusing on the development of genetic switches using CRISPR technology. Additional experience includes internships and student roles at prestigious organizations such as the University of Washington, Merck, and the Paul-Ehrlich-Institut, complemented by academic qualifications in Technical Biology (M.S.) and Biology (B.S.) from Technische Universität Darmstadt.
This person is not in any offices
BioSpring GmbH
BioSpring is a leading industry expert in oligonucleotide science and technology, specializing in high-quality cGMP manufacturing and analytics for commercial programs and clinical phases I-III, in addition to preclinical material supply and diagnostic manufacturing. We are a privately owned company of ~600 employees committed to providing expert support through all phases and regulatory filings, including highly flexible and customizable solutions to accelerate therapeutic programs through the entire drug development lifecycle. Headquartered in the center of Europe, in Frankfurt, Germany, we are an international company with a subsidiary in the United States and a local presence in Japan. Our global clients can rely on our quality and expertise, guided by our passion for innovation and more than 27 years of experience. Our aim is a highly collaborative partnership to unleash the full potential of our clients’ technology – making great strides and breakthroughs possible. We are driven by our desire for a healthier world. Restoring hope in patients living with debilitating diseases is our daily motivation to progress novel nucleic acid-based therapies to their commercial promise. Privacy notice: https://www.biospring.de/datenschutz-socialmedia/